Omalizumab.

Article Details

Citation Copy to clipboard

Kumar C, Zito PM

Omalizumab.

PubMed ID

]

Abstract

Omalizumab received initial approval from the U.S. Food and Drug Administration (FDA) in 2003 for the treatment of moderate-to-severe asthma. Subsequently, in 2014, the drug was also approved for use in patients with chronic idiopathic or spontaneous urticaria in the United States and Europe. Omalizumab is a recombinant humanized immunoglobulin G1 (IgG1) monoclonal anti-IgE antibody utilized to treat allergic asthma and chronic urticaria. This medication works by interacting with the high-affinity receptor Fc-epsilon-RI, typically found on eosinophils, mast cells, and basophils, therefore playing a critical role in preventing the allergic cascade. As a result, omalizumab plays a vital role in managing moderate-to-severe IgE-mediated asthma and, more recently, in treating chronic urticaria. This activity will comprehensively cover the indications, contraindications, mechanisms of action, pharmacokinetics, adverse effects, warnings, precautions, and monitoring requirements of omalizumab. In addition, this activity will also provide updates on some of the critical studies implemented primarily for asthma and include information on urticarial reactions.

DrugBank Data that Cites this Article

Drugs: Omalizumab